title: L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
authors: University Hospital of Schleswig-Holstein and Klinikum Bad Bramstedt, 24576 Bad Bramstedt, Germany. F.Moosig@klinikumbb.de
authors: Frank
authors: F
authors: Moosig
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D015267:Churg-Strauss Syndrome / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005544:Forecasting; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D015848:Interleukin-5; D000069283:Rituximab; D003520:Cyclophosphamide; C434107:mepolizumab